RU58841: Is it easy to get or is it an impossible mission?

The elusive promise: What is RU58841?

RU58841 is a non-steroidal anti-androgen (NSAA) first described in the 1990s and studied as a possible treatment for androgenetic alopecia (male and female pattern hair loss). In laboratory and animal work it binds to androgen receptors, competing with dihydrotestosterone (DHT) — a derivative of testosterone — which is associated with the follicle miniaturization behind pattern hair loss. It was designed as a topical compound intended to act at the site of application. Whether that design holds in people is unknown: no human pharmacokinetic study of RU58841 has been published, and rat work on this class of anti-androgens found a shared metabolite with systemic activity (Cousty-Berlin et al., 1994). Local-only action should be treated as a design intention, not a measured fact.

Why isn't RU58841 on pharmacy shelves?

RU58841 never advanced past early-stage research. Development stopped, and no company has published a reason. A widely-circulated Reddit account of a conversation with someone involved in the programme says the reason was commercial rather than safety-related; that account is unverified, and in any case the absence of a stated safety problem is not evidence of safety. Nothing was ever measured in a large human trial.

Unlike minoxidil and finasteride, which have regulatory approval for hair loss, RU58841 is not approved for medical use anywhere in the world. It is sold as a "research chemical" — meaning it is not manufactured, tested or released under pharmaceutical quality controls, and no regulator checks what is in a given vial. Purity, concentration, contaminants and legality are all unverified.

User experience

Community discussions about how easy or difficult it is to obtain hair-loss treatments show a wide range of experiences. A common theme is that off-label prescriptions can be hard to get. One woman with androgenic alopecia described using birth control, spironolactone, finasteride and oral minoxidil, and said that when she asked to switch to dutasteride and bicalutamide — both used off-label in women — her new dermatologist declined. Users often read this as doctors being reluctant to go beyond approved options. Clinicians describe the same decision differently: dutasteride and bicalutamide carry their own risks, bicalutamide requires liver monitoring, and both are teratogenic, so a refusal may reflect a considered judgement about that specific patient rather than blanket conservatism.

Other community members describe going to a different clinician for a second opinion, or using telehealth services for approved treatments such as finasteride or minoxidil. Users caution each other to check that any such service is properly licensed.

Some describe relatively smooth experiences getting topical finasteride or oral minoxidil after explaining their treatment history, and say that coming prepared — being able to name the evidence and explain why they wanted a particular treatment — made the conversation easier.

Some community members who cannot get a prescription buy unapproved compounds such as RU58841 from unregulated suppliers instead. That market is outside pharmaceutical quality control, nothing about the product is verified, and the risk sits entirely with the buyer.

The hunt begins: How accessible is RU58841?

The short answer is that RU58841 is not accessible as a medicine at all. It cannot be prescribed or dispensed for hair loss, because no regulator has approved it for any human use, and no pharmacy stocks it.

What does exist is an unregulated market in material sold for laboratory use. Because nothing in that market is subject to pharmaceutical quality control, a buyer has no way to confirm identity, purity or concentration — a real concern for anything applied to skin. Independent testing of unregulated research-chemical markets has repeatedly found mislabelled and impure product; we have not been able to verify the specific figure this article previously quoted, so it has been removed rather than repeated.

Legal status varies by country and can change. RU58841 is generally not a scheduled controlled substance, but "not scheduled" is not the same as "legal to import or use", and personal importation of unapproved substances is restricted in many jurisdictions.

What does science say? The studies behind RU58841

The published RU58841 literature is small and entirely preclinical. What exists:

• Year: 1994
  Method: Laboratory and animal models
  Population: Animal models of androgen-dependent skin conditions
  Duration: Not stated in the abstract
  Findings: Battmann and colleagues (1994) described RU 58841 as a topical antiandrogen with strong local activity and proposed it as a candidate for acne, androgenetic alopecia and hirsutism. This is a description of early-stage animal pharmacology, not a demonstration of benefit in people.

• Year: 1995
  Method: Animal study
  Population: Hamster sebaceous gland model
  Duration: Not stated in the abstract
  Findings: Matias and Gaillard (1995) reported local inhibition of sebaceous gland growth from topically applied RU 58841 — a marker of androgen blockade at the site of application. Sebaceous glands are not hair follicles, and hamster skin is not human skin.

• Year: 1997
  Method: Human scalp grafts on nude mice
  Population: Balding human scalp grafts maintained on testosterone-conditioned nude mice
  Duration: Not stated in the abstract
  Findings: De Brouwer and colleagues (1997) ran a controlled study of RU58841's effect on human hair production in this graft model. It is the closest thing to human tissue data that exists, and it is still not a trial in living people.

• Year: 1998
  Method: Cell work plus an animal study
  Population: Prostate PC3 cells; bald scalp of stumptailed macaques
  Duration: Not stated in the abstract
  Findings: Pan and colleagues (1998) evaluated RU58841 as an anti-androgen in cells and as a topical anti-alopecia agent in macaques. Macaque results have historically translated poorly and imperfectly to humans.

Note: these are early-stage studies with real limitations. Animal models do not reliably mimic human skin and hair growth, cell work cannot account for absorption through the scalp or for long-term effects, and no large-scale human clinical trial of RU58841 has ever been completed or published. That gap covers both safety and efficacy.

The bottom line: Miracle cure or mission impossible?

RU58841 has a mechanism that interests researchers and communities, but the evidence stops at animal and tissue studies. There are no human trial data on whether it works, no human data on how much is absorbed, and no data at all on long-term safety. Alongside that, the only material available is unregulated and unverified.

Talk to a doctor or pharmacist before starting, stopping or combining RU58841 or any hair-loss treatment — including if you are already using something bought outside the medical system, since a clinician can only account for what they know about. If an approved treatment has been refused, asking why, or seeking a second opinion, is a safer path than an unregulated one.

References

Battmann, T., Bonfils, A., Branche, C., et al. (1994). RU 58841, a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism. The Journal of Steroid Biochemistry and Molecular Biology, 48(1), 55-60. https://pubmed.ncbi.nlm.nih.gov/8136306/

Matias, J. R., & Gaillard, M. (1995). Local inhibition of sebaceous gland growth by topically applied RU 58841. Annals of the New York Academy of Sciences, 761, 56-65. https://pubmed.ncbi.nlm.nih.gov/7625751/

De Brouwer, B., Tetelin, C., Leroy, T., et al. (1997). A controlled study of the effects of RU58841, a non-steroidal antiandrogen, on human hair production by balding scalp grafts maintained on testosterone-conditioned nude mice. British Journal of Dermatology, 137(5), 699-702. https://pubmed.ncbi.nlm.nih.gov/9415227/

Pan, H. J., Wilding, G., Uno, H., et al. (1998). Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques. Endocrine, 9(1), 39-43. https://pubmed.ncbi.nlm.nih.gov/9798729/

Cousty-Berlin, D., Bergaud, B., Bruyant, M. C., et al. (1994). Preliminary pharmacokinetics and metabolism of novel non-steroidal antiandrogens in the rat: relation of their systemic activity to the formation of a common metabolite. The Journal of Steroid Biochemistry and Molecular Biology, 51(1-2), 47-55. https://pubmed.ncbi.nlm.nih.gov/7947350/

U.S. Food and Drug Administration (FDA). (n.d.). Drug Approval Process. Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs

Reddit user. (2024, April 2). Men on here: did you have trouble getting a derm to prescribe you "off-label" meds? Retrieved from https://reddit.com/r/tressless/comments/1btyg3s

Reddit user. (2021, May 18). I spoke to the Guy who did the Ru58841 (PSK-3841) research. Retrieved from https://reddit.com/r/tressless/comments/nfig28